8-K: Century Therapeutics Regains Nasdaq Compliance, Halts Reverse Split

Century Therapeutics, Inc. announced it has regained compliance with Nasdaq's minimum bid price rule, leading to the decision not to proceed with a previously approved reverse stock split.

Summary

• Century Therapeutics, Inc. held a special meeting of stockholders on January 22, 2026.
• Stockholders approved an amendment to the company's charter to effect a reverse stock split by a ratio of any whole number between 1-for-5 and 1-for-30, with discretion given to the Board of Directors.
• The proposal received 55,089,478 votes for, 5,361,020 against, and 27,055 abstentions.
• On the same day, the company received notification from Nasdaq Stock Market LLC that it had regained compliance with Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share.
• As a result of regaining Nasdaq compliance, the company does not intend to effect the approved reverse stock split.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the company successfully regaining Nasdaq compliance and avoiding the need for a reverse stock split, which can often be perceived negatively by the market.

Positives

• Regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share.
• Now in compliance with all applicable Nasdaq continued listing standards.
• The company will not need to implement the approved reverse stock split, avoiding potential negative perceptions or impacts often associated with such an action.

Negatives

• The company previously faced non-compliance with Nasdaq's minimum bid price rule, necessitating the proposal for a reverse stock split.

Future Outlook

The company does not intend to effect the reverse stock split that was approved by stockholders, as it has regained compliance with Nasdaq's minimum bid price requirement.

Management Comments

• The company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company to maintain a minimum closing bid price of $1.00 per share and that it is now in compliance with all applicable continued listing standards.
• As a result, the Company does not intend to effect the reverse stock split as approved by the stockholders at the Special Meeting.

Industry Context

For biotechnology and pharmaceutical companies, maintaining a Nasdaq listing is crucial for liquidity, investor confidence, and access to capital markets. Non-compliance with listing rules, particularly minimum bid price, can signal underlying operational or financial challenges and often leads to reverse stock splits to artificially boost share price, which can be viewed negatively by investors. Regaining compliance without needing a reverse split is generally a positive development.

Corporate Governance

Stakeholder Impact

• Shareholders: Benefit from the company maintaining its Nasdaq listing, which ensures liquidity and market visibility. Avoiding a reverse stock split can prevent potential dilution concerns or negative market perception often associated with such actions.
• Employees: Continued listing on a major exchange can contribute to company stability and morale.

Next Steps

• The company will not proceed with the previously approved reverse stock split.

Key Dates

Keywords

Century Therapeutics, IPSC, Nasdaq, reverse stock split, stock market compliance, corporate governance, special meeting, shareholder vote, biotech, pharmaceutical